Nephro-Urology Monthly

Published by: Kowsar

Chronic Graft Loss and Death in Patients With Post-Transplant Malignancy in Living Kidney Transplantation: A Competing Risk Analysis

Mahmoud Salesi 1 , Zohreh Rostami 2 , Abbas Rahimi Foroushani 1 , Ali Reza Mehrazmay 2 , Jamile Mohammadi 3 , Behzad Einollahi 2 , Saeed Asgharian 4 and Mohammad Reza Eshraghian 1 , *
Authors Information
1 Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, IR Iran
2 Nephrology and Urology Research Center, Baqiyatallah University of Medical Sciences, Tehran, IR Iran
3 Department of Psychology, Faculty of Humanities, Tarbiat Modares University, Tehran, IR Iran
4 Salamat Hospital, Ahvaz University of Medical Sciences, Ahvaz, IR Iran
Article information
  • Nephro-Urology Monthly: March 01, 2014, 6 (2); e14302
  • Published Online: March 10, 2014
  • Article Type: Research Article
  • Received: August 19, 2013
  • Revised: September 12, 2013
  • Accepted: September 22, 2013
  • DOI: 10.5812/numonthly.14302

To Cite: Salesi M, Rostami Z, Rahimi Foroushani A, Mehrazmay A R, Mohammadi J, et al. Chronic Graft Loss and Death in Patients With Post-Transplant Malignancy in Living Kidney Transplantation: A Competing Risk Analysis, Nephro-Urol Mon. 2014 ; 6(2):e14302. doi: 10.5812/numonthly.14302.

Copyright © 2014, Nephrology and Urology Research Center. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
  • 1. Ghods AJ, Savaj S. Iranian model of paid and regulated living-unrelated kidney donation. Clin J Am Soc Nephrol. 2006; 1(6): 1136-45[DOI][PubMed]
  • 2. Haghighi AN, Broumand B, D'Amico M, Locatelli F, Ritz E. The epidemiology of end-stage renal disease in Iran in an international perspective. Nephrol Dial Transplant. 2002; 17(1): 28-32[PubMed]
  • 3. Feng WW, Wang TN, Chen HC, Ho JC, Ko YC. Malignancies after renal transplantation in southern Taiwan: experience in one centre. BJU Int. 2007; 99(4): 825-9[DOI][PubMed]
  • 4. Marcen R. Immunosuppressive drugs in kidney transplantation: impact on patient survival, and incidence of cardiovascular disease, malignancy and infection. Drugs. 2009; 69(16): 2227-43[DOI][PubMed]
  • 5. Wimmer CD, Rentsch M, Crispin A, Illner WD, Arbogast H, Graeb C, et al. The janus face of immunosuppression - de novo malignancy after renal transplantation: the experience of the Transplantation Center Munich. Kidney Int. 2007; 71(12): 1271-8[DOI][PubMed]
  • 6. Navarro MD, Lopez-Andreu M, Rodriguez-Benot A, Aguera ML, Del Castillo D, Aljama P. Cancer incidence and survival in kidney transplant patients. Transplant Proc. 2008; 40(9): 2936-40[DOI][PubMed]
  • 7. Gandhi MJ, Strong DM. Donor derived malignancy following transplantation: a review. Cell Tissue Bank. 2007; 8(4): 267-86[DOI][PubMed]
  • 8. Vegso G, Toth M, Hidvegi M, Toronyi E, Langer RM, Dinya E, et al. Malignancies after renal transplantation during 33 years at a single center. Pathol Oncol Res. 2007; 13(1): 63-9[PubMed]
  • 9. Stratta P, Morellini V, Musetti C, Turello E, Palmieri D, Lazzarich E, et al. Malignancy after kidney transplantation: results of 400 patients from a single center. Clin Transplant. 2008; 22(4): 424-7[DOI][PubMed]
  • 10. Hu XP, Ma LL, Wang Y, Yin H, Wang W, Yang XY, et al. Rapamycin instead of mycophenolate mofetil or azathioprine in treatment of post-renal transplantation urothelial carcinoma. Chin Med J (Engl). 2009; 122(1): 35-8[PubMed]
  • 11. Guba M, von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, Hornung M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med. 2002; 8(2): 128-35[DOI][PubMed]
  • 12. Dantal J, Pohanka E. Malignancies in renal transplantation: an unmet medical need. Nephrol Dial Transplant. 2007; 22 Suppl 1-10[DOI][PubMed]
  • 13. Iranian network for organ procurement.
  • 14. Lindholm A, Albrechtsen D, Frodin L, Tufveson G, Persson NH, Lundgren G. Ischemic heart disease--major cause of death and graft loss after renal transplantation in Scandinavia. Transplantation. 1995; 60(5): 451-7[PubMed]
  • 15. Hirata M, Cho YW, Cecka JM, Terasaki PI. Patient death after renal transplantation--an analysis of its role in graft outcome. Transplantation. 1996; 61(10): 1479-83[PubMed]
  • 16. Matas AJ, Gillingham KJ, Sutherland DE. Half-life and risk factors for kidney transplant outcome--importance of death with function. Transplantation. 1993; 55(4): 757-61[PubMed]
  • 17. West M, Sutherland DE, Matas AJ. Kidney transplant recipients who die with functioning grafts: serum creatinine level and cause of death. Transplantation. 1996; 62(7): 1029-30[PubMed]
  • 18. Sato K, Tadokoro F, Ishida K, Matsuzawa K, Nakayama Y, Yokota K, et al. Causes of death after renal transplantation: a long-term follow-up study. Transplant Proc. 1994; 26(4): 2017-8[PubMed]
  • 19. Kim YS, Oh CK, Park K. Causes of early or late patient death after living donor renal transplantation. Transplant Proc. 1994; 26(4): 2019-20[PubMed]
  • 20. Hill MN, Grossman RA, Feldman HI, Hurwitz S, Dafoe DC. Changes in causes of death after renal transplantation, 1966 to 1987. Am J Kidney Dis. 1991; 17(5): 512-8[PubMed]
  • 21. Gorlen T, Abdelnoor M, Enger E, Halvorsen S, Leivestad T, Malm OJ, et al. Long term morbidity and mortality after kidney transplantation. Scand J Urol Nephrol. 1992; 26(4): 397-401[PubMed]
  • 22. Dlugosz BA, Bretan PN, Jr, Novick AC, Steinmuller DR, Streem SB, Badwar K, et al. Causes of death in kidney transplant recipients: 1970 to present. Transplant Proc. 1989; 21(1 Pt 2): 2168-70[PubMed]
  • 23. Washer GF, Schroter GP, Starzl TE, Weil R, 3rd. Causes of death after kidney transplantation. JAMA. 1983; 250(1): 49-54[PubMed]
  • 24. Einollahi B, Lessan-Pezeshki M, Nourbala MH, Simforoosh N, Pourfarziani V, Nemati E, et al. Kaposi's sarcoma following living donor kidney transplantation: review of 7,939 recipients. Int Urol Nephrol. 2009; 41(3): 679-85[DOI][PubMed]
  • 25. Braun WE, Yadlapalli NG. The spectrum of long-term renal transplantation: Outcomes, complications, and clinical studies. Transplantation Rev. 2002; 16(1): 22-50
  • 26. Mazuecos A, Munoz Terol JM, Garcia Alvarez T, Sola E, Rodriguez Benot A, Dsuna A, et al. Increase in malignancies as cause of death in renal transplant patients. Transplant Proc. 2009; 41(6): 2159-62[DOI][PubMed]
  • 27. Tiong HY, Goldfarb DA, Kattan MW, Alster JM, Thuita L, Yu C, et al. Nomograms for predicting graft function and survival in living donor kidney transplantation based on the UNOS Registry. J Urol. 2009; 181(3): 1248-55[DOI][PubMed]
  • 28. Harada KM, Mandia-Sampaio EL, de Sandes-Freitas TV, Felipe CR, Park SI, Pinheiro-Machado PG, et al. Risk factors associated with graft loss and patient survival after kidney transplantation. Transplant Proc. 2009; 41(9): 3667-70[DOI][PubMed]
  • 29. Satagopan JM, Ben-Porat L, Berwick M, Robson M, Kutler D, Auerbach AD. A note on competing risks in survival data analysis. Br J Cancer. 2004; 91(7): 1229-35[DOI][PubMed]
  • 30. Einollahi B, Rostami Z, Nourbala MH, Lessan-Pezeshki M, Simforoosh N, Nemati E, et al. Incidence of malignancy after living kidney transplantation: a multicenter study from iran. J Cancer. 2012; 3: 246-56[DOI][PubMed]
  • 31. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J of American. 1999; 94(446): 496-509
  • 32. Prentice RL, Kalbfleisch JD, Peterson AV, Jr., Flournoy N, Farewell VT, Breslow NE. The analysis of failure times in the presence of competing risks. Biometrics. 1978; 34(4): 541-54[PubMed]
  • 33. Kal bfleisch JD, Prentice RL. The statistical analysis of failure time data. 2002;
  • 34. Pintilie M. Competing risks: A practical perspective. 2006;
  • 35. Beyersmann J, Schumacher M. Time-dependent covariates in the proportional subdistribution hazards model for competing risks. Biostatistics. 2008; 9(4): 765-76[DOI][PubMed]
  • 36. Latouche A, Porcher R, Chevret S. A note on including time-dependent covariate in regression model for competing risks data. Biom J. 2005; 47(6): 807-14[PubMed]
  • 37. Grunkemeier GL, Jin R, Eijkemans MJ, Takkenberg JJ. Actual and actuarial probabilities of competing risks: apples and lemons. Ann Thorac Surg. 2007; 83(5): 1586-92[DOI][PubMed]
  • 38. Einollahi B, Nemati E, Lessan-Pezeshki M, Simforoosh N, Nourbala MH, Rostami Z, et al. Skin cancer after renal transplantation: Results of a multicenter study in Iran. Ann Transplant. 2010; 15(3): 44-50[PubMed]
  • 39. Alonso A, Oliver J. Causes of death and mortality risk factors. Nephrol Dial Transplant. 2004; 19 Suppl 3-10[DOI][PubMed]
  • 40. Briganti EM, Wolfe R, Russ GR, Eris JM, Walker RG, McNeil JJ. Graft loss following renal transplantation in Australia: is there a centre effect? Nephrol Dial Transplant. 2002; 17(6): 1099-104[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments